{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121459","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.652495+00:00","generated_at":"2026-05-30T05:18:51.096080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx Q3 revenue $139M (+42% YoY); Breakthrough Therapy for setrusumab; DTX401 crossover 62% cornstarch reduction","bullets":["Total revenue $139M, up 42% YoY; Crysvita $98M (+31%), Dojolvi $21M (+29%), Evkeeza $11M.","Net loss $134M ($1.40/share) vs $160M ($2.23) YoY; operating cash burn $67M in Q3.","FY2024 guidance reaffirmed: total revenue $530-550M, Crysvita upper end $375-400M, Dojolvi $75-80M.","Setrusumab (UX143) granted FDA Breakthrough Therapy for osteogenesis imperfecta based on 67% fracture reduction.","DTX401 Phase 3 crossover patients showed 62% mean cornstarch reduction at week 30; BLA submission planned mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121459","json":"https://secwatch.observer/filing/0000950170-24-121459.json","markdown":"https://secwatch.observer/filing/0000950170-24-121459.md","text":"https://secwatch.observer/filing/0000950170-24-121459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024121459/0000950170-24-121459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024121459/rare-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:18:51.096080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}